
Hyperspectral Imaging for Alzheimer's Disease
Stage: Pre-seed prototype stage
Area: Diagnostics
Status: Ongoing
Patent: Two patents on the camera technology secured (P436042SE00 & SE542835C2)
Background
Alzheimer’s Disease is the main cause of dementia worldwide. There is currently no easy way to diagnose it. As a result, patients get diagnosed too late, once their cognitive decline has started. Mantis Photonics AB is developing a hyperspectral camera for retinal imaging for the early screening of Alzheimer Disease via the detection of the Amyloid beta peptide. The retina displays similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology. Hence, the eye provides a unique window to the central nervous system without the need for expensive, invasive, and/or potentially harmful examinations.
Aims, Hypothesis & Results
This camera will fit on a fundoscope routinely used by opticians and ophthalmologists. It will be developed to detect patients with high levels of amyloid up to 15 years before their cognitive ability declines. Earlier diagnosis will considerably increase chances to adopt a healthy lifestyle to reduce/postpone the risk of getting Alzheimer as well as increasing the chance of getting treatment in time.
Timeline
- Developing improved version of the camera
- Clinical and preclinical verification testing
Required Funding: €30000
Status: Ongoing
Duration: 24 Months
Measuring amyloid plaques in the brain directly with amyloid PET scan. This is a lengthy and costly procedure. FDA approved retinal camera by Optina (FDA 510(k) clearance for its Mydriatic Hyperspectral Retinal Camera (MHRC-C1) in 2020). This camera uses its own light source; it cannot be mounted on a fundoscope and is very expensive. Estimated at >50k Euro, hindering mass adoption. Mantis Photonics is developing a hyperspectral camera that can be easily added to routine fundoscopy at opticians and ophthalmologists for the detection of amyloid deposits in the retina. There is peer-reviewed proof-of-concept research supporting hyperspectral retinal imaging to classify AD patients vs controls. The team is seeking bridge funding until their seed round later this year to collect in vivo data in mice/humans of their camera.
VitaDAO Board Evaluation Writeup
The retina amyloid detection camera is already FDA approved and there is peer-reviewed proof-of-concept research supporting hyperspectral retinal imaging to classify AD patients. The project has future potential to become a platform diagnostic for several aging related and other conditions: AMD, diabetic retinopathy, etc. The team is strong with extensive scientific expertise in the field. The current valuation of Mantis Photonics is low ($3-4M). The product is still in the prototype stage and more data is needed on its performance in mice and humans.

Non Consectetur Necessitatibus
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

Eum Harum Asperiores Id
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

Ex Temporibus Perferendis
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

Dolorum Quia
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

Earum Est Dolorem
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

Culpa Possimus
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

Aperiam Et Quis Et
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

Voluptas Quam Sapiente
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

Aut Accusantium Ut
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

Nisi
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Discover more projects & initiatives

Humanity
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

Matrix Bio
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.

BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

ExcepGen Inc - RNA therapeutics for longevity
ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.